Kymera Therapeutics, Inc. KYMR
121.52 USD -4.33 (-3.44%)
Regular-session close
121.52 0.00 0.00%
After hours · Nov 17, 4:00 PM ET
119.30 Day range 126.19
64.10 52-week range 138.86
- YTD
- +56.18%
- 1 year
- +89.58%
News
benzinga.com Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170 Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $139 to $170.
benzinga.com Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150 Truist Securities analyst Srikripa Devarakonda reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $136 to $150.
benzinga.com RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116 RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Sector Perform and raises the price target from $112 to $116.
benzinga.com BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139 BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $134 to $139.
seekingalpha.com Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
marketbeat.com Kymera Therapeutics Q3 Earnings Call Highlights Kymera Therapeutics NASDAQ: KYMR reported third-quarter results and outlined progress across its clinical pipeline, including phase I healthy-volunteer data for KT-579, an oral degrader targeting…benzinga.com Kymera Therapeutics Q3 EPS $(1.32) Misses $(1.27) Estimate Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.27) by 3.94 percent. This is a 40.43 percent decrease over losses…
globenewswire.com Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile
globenewswire.com Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026 WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader…benzinga.com Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146 Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $135 to $146.
globenewswire.com Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader…
zacks.com Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth? Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
prnewswire.com SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation…
prnewswire.com Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR)…
seekingalpha.com Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
zacks.com Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
defenseworld.net Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR Atlas Venture Life Science Advisors LLC lessened its stake in Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 37.8% in the second quarter, according to the company in its most recent disclosure with the…
zacks.com Can KT-621 Mark a Turning Point for Kymera Therapeutics? KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
globenewswire.com Kymera Therapeutics to Participate in Upcoming September Investor Conferences WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader…
globenewswire.com Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial…
defenseworld.net 215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp Bank of New York Mellon Corp purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) in the undefined quarter, according to its most recent filing with the Securities and…
zacks.com KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
seekingalpha.com Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
marketbeat.com Kymera Therapeutics Q2 Earnings Call Highlights Kymera Therapeutics NASDAQ: KYMR said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by…
zacks.com Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.
